Anti-HER2 scFv Expression in Escherichia coli SHuffle®T7 Express Cells: Effects on Solubility and Biological Activity
- 46 Downloads
Breast cancer is the second most commonly diagnosed cancer, worldwide. Human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer is correlated with poor prognosis. HER2-targeting monoclonal antibodies resulted in longer survival of HER2+ breast cancer. Single-chain variable fragment (scFv) demonstrates improved penetrability into tumors. Due to the presence of two disulfide bond, scFv expression in reducing bacterial cytoplasm may cause formation of inclusion bodies. Disulfide bond can be formed properly in cytoplasm of SHuffle® strain as it is trxB−, gor−, and overexpresses cytoplasmic DsbC chaperone. In this study, the anti-HER2 scFv was successfully expressed and purified in BL21 (DE3) and SHuffle® cells. Here, significant higher soluble anti-HER2 scFv was produced in SHuffle® than in BL21 strain. The specific binding of anti-HER2 scFv to HER2 was shown by flow cytometry analysis and ELISA. Moreover, it was demonstrated that the anti-HER2 scFv produced in SHuffle® binds to HER2 at higher level as compared to that expressed in BL21 cells. Furthermore, competitive ELISA-based study suggested that anti-HER2 scFv recognizes the same epitope of HER2 receptor as the trastuzumab antibody. Our findings indicated that correct disulfide bond formation in SHuffle® strain can result in enhanced solubility and higher biological activity level of anti-HER2 scFv.
KeywordsBreast cancer HER2 scFv SHuffle® strain Solubility Biological activity
This work was supported by the grant from the research deputy of Shahid Beheshti University of Medical Sciences (SBMU).
Compliance with Ethical Standards
Conflict of interest
All authors declare that they have no conflict of interest.
- 11.Akbari, V., Sadeghi, H. M. M., Jafrian-Dehkordi, A., Abedi, D., & Chou, C. P. (2014). Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli. Journal of Industrial Microbiology and Biotechnology, 41, 947–956.PubMedCrossRefGoogle Scholar
- 12.Cao, Y., Marks, J. D., Huang, Q., Rudnick, S. I., Xiong, C., Hittelman, W. N., et al. (2012). Single-chain antibody-based immunotoxins targeting Her2/neu: Design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Molecular Cancer Therapeutics, 11, 143–153.PubMedCrossRefGoogle Scholar
- 22.Jalomo-Khayrova, E., Mares, R. E., Muñoz, P. L., Meléndez-López, S. G., Rivero, I. A., & Ramos, M. A. (2018). Soluble expression of an amebic cysteine protease in the cytoplasm of Escherichia coli SHuffle Express cells and purification of active enzyme. BMC Biotechnology, 18, 20.PubMedPubMedCentralCrossRefGoogle Scholar
- 29.Safarpour, H., Banadkoki, S. B., Keshavarzi, Z., Morowvat, M. H., Soleimanpour, M., Pourmolaei, S., et al. (2017). Expression analysis and ATR-FTIR characterization of the secondary structure of recombinant human TNF-α from Escherichia coli SHuffle® T7 Express and BL21 (DE3) cells. International Journal of Biological Macromolecules, 99, 173–178.PubMedCrossRefGoogle Scholar
- 30.Balandin, T. G., Edelweiss, E., Andronova, N. V., Treshalina, E. M., Sapozhnikov, A. M., & Deyev, S. M. (2011). Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts. Investigational New Drugs, 29, 22–32.PubMedCrossRefGoogle Scholar
- 35.Jaliani, H. Z., Farajnia, S., Safdari, Y., Mohammadi, S. A., Barzegar, A., & Talebi, S. (2014). Optimized condition for enhanced soluble-expression of recombinant mutant anabaena variabilis phenylalanine ammonia lyase. Advanced Pharmaceutical Bulletin, 4, 261–266.Google Scholar
- 36.Naderi, S., Alikhani, M. Y., Karimi, J., Shabab, N., Mohamadi, N., Jaliani, H. Z., et al. (2015). Cytoplasmic expression, optimization and catalytic activity evaluation of recombinant mature lysostaphin as an anti-staphylococcal therapeutic in Escherichia coli. Acta Medica International, 2, 72–77.CrossRefGoogle Scholar
- 44.Schein, C. H., & Noteborn, M. H. (1988). Formation of soluble recombinant proteins in Escherichia coli is favored by lower growth temperature. Bio/technology, 6, 291–294.Google Scholar
- 46.Zhu, Y. Q., Tong, W. Y., Wei, D. Z., Zhou, F., & Zhao, J. B. (2007). Environmental stimuli on the soluble expression of anti-human ovarian carcinoma × anti-human CD3 single-chain bispecific antibody in recombinant Escherichia coli. Biochemical Engineering Journal, 37, 184–19144.CrossRefGoogle Scholar